{"id":"atazanavir-week-24-switch","safety":{"commonSideEffects":[{"rate":"35–50","effect":"Hyperbilirubinemia"},{"rate":"5–10","effect":"Jaundice"},{"rate":"10–15","effect":"Nausea"},{"rate":"10–15","effect":"Diarrhea"},{"rate":"5–10","effect":"Headache"},{"rate":"5–10","effect":"Rash"},{"rate":"1–2","effect":"Nephrolithiasis"}]},"_chembl":{"chemblId":"CHEMBL1200678","moleculeType":"Small molecule","molecularWeight":"802.95"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atazanavir binds to the active site of HIV protease, an enzyme essential for processing viral precursor proteins into mature, functional viral components. By inhibiting this protease, the drug prevents the formation of infectious viral particles, thereby reducing viral load and slowing disease progression. It is typically used as part of combination antiretroviral therapy (cART) in HIV-infected patients.","oneSentence":"Atazanavir is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins and stopping HIV replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:02:48.172Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-experienced and treatment-naïve adults (as part of combination antiretroviral therapy)"}]},"trialDetails":[{"nctId":"NCT05502341","phase":"PHASE2, PHASE3","title":"Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-08-16","conditions":"HIV-1-infection","enrollment":689},{"nctId":"NCT02397096","phase":"PHASE3","title":"Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-06-09","conditions":"HIV-1 Infection","enrollment":673},{"nctId":"NCT02542852","phase":"PHASE2","title":"A Study of a Nucleoside Sparing Regimen in HIV-1 Infected Patients With Detectable Viremia","status":"COMPLETED","sponsor":"Castagna Antonella","startDate":"2015-09","conditions":"HIV-1 Infection","enrollment":10},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT00756730","phase":"PHASE4","title":"Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r","status":"COMPLETED","sponsor":"Community Research Initiative of New England","startDate":"2008-09","conditions":"HIV Infections","enrollment":49},{"nctId":"NCT01252940","phase":"PHASE3","title":"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-11","conditions":"HIV-1 Infection","enrollment":482},{"nctId":"NCT00225017","phase":"PHASE3","title":"Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2005-06","conditions":"HIV Infection, Hyperlipidemia","enrollment":50},{"nctId":"NCT00067782","phase":"PHASE3","title":"A Phase IIIB Study Evaluating the Effect on Serum Lipids Following a Switch to Atazanavir in HIV Infected Subjects Evidencing Virologic Suppression on Their First PI-Based Antiretroviral Therapy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2002-12","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00120393","phase":"PHASE3","title":"Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-01","conditions":"HIV Infections","enrollment":192}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Reyataz"],"phase":"phase_3","status":"active","brandName":"Atazanavir (Week 24 switch)","genericName":"Atazanavir (Week 24 switch)","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Atazanavir is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins and stopping HIV replication. Used for HIV-1 infection in treatment-experienced and treatment-naïve adults (as part of combination antiretroviral therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}